EA201390015A1 - Композиции и способы ингибирования пути jak - Google Patents

Композиции и способы ингибирования пути jak

Info

Publication number
EA201390015A1
EA201390015A1 EA201390015A EA201390015A EA201390015A1 EA 201390015 A1 EA201390015 A1 EA 201390015A1 EA 201390015 A EA201390015 A EA 201390015A EA 201390015 A EA201390015 A EA 201390015A EA 201390015 A1 EA201390015 A1 EA 201390015A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
jak
compounds
inhibiting path
Prior art date
Application number
EA201390015A
Other languages
English (en)
Inventor
Хуэй ЛИ
Тило Дж. Хекродт
Янь Чэнь
Даррен Джон Макмартри
Ванесса Тэйлор
Раджиндер Сингх
Пинюй Дин
Роуз Йен
Original Assignee
Райджел Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Райджел Фармасьютикалз, Инк. filed Critical Райджел Фармасьютикалз, Инк.
Publication of EA201390015A1 publication Critical patent/EA201390015A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предложены соединения формулы I, композиции, содержащие указанные соединения, и способы применения соединений и композиций для лечения состояний, для которых модулирование сигнального пути JAK или ингибирование JAK киназ, в частности JAK2 и JAK3, терапевтически оправданно. Также предложены способы получения указанных соединений.
EA201390015A 2010-07-28 2011-07-27 Композиции и способы ингибирования пути jak EA201390015A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36857010P 2010-07-28 2010-07-28
PCT/US2011/045609 WO2012015972A1 (en) 2010-07-28 2011-07-27 Compositions and methods for inhibition of the jak pathway

Publications (1)

Publication Number Publication Date
EA201390015A1 true EA201390015A1 (ru) 2013-07-30

Family

ID=44504225

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390015A EA201390015A1 (ru) 2010-07-28 2011-07-27 Композиции и способы ингибирования пути jak

Country Status (20)

Country Link
US (8) US8343954B2 (ru)
EP (1) EP2598500B1 (ru)
JP (2) JP6073221B2 (ru)
KR (1) KR101937495B1 (ru)
CN (1) CN103201280B (ru)
AR (2) AR082408A1 (ru)
AU (1) AU2011282742B2 (ru)
BR (1) BR112013001632B1 (ru)
CA (1) CA2804199C (ru)
DK (1) DK2598500T3 (ru)
EA (1) EA201390015A1 (ru)
ES (1) ES2880622T3 (ru)
IL (1) IL223855A (ru)
MX (2) MX347331B (ru)
PL (1) PL2598500T3 (ru)
PT (1) PT2598500T (ru)
RU (1) RU2672100C2 (ru)
TW (1) TWI582090B (ru)
WO (1) WO2012015972A1 (ru)
ZA (1) ZA201300388B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
MX2011007750A (es) * 2009-01-23 2011-09-29 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la ruta jak.
PT2598500T (pt) * 2010-07-28 2021-07-22 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
CA2867760C (en) 2012-04-04 2021-10-05 Rigel Pharmaceuticals, Inc. Indolizinyl derivatives as protein kinase c inhibitors and uses thereof
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
US20140213555A1 (en) * 2013-01-25 2014-07-31 Rigel Pharmaceuticals, Inc. Compounds and method for treating autoimmune diseases
JP6421170B2 (ja) 2013-03-14 2018-11-07 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
US20160159774A1 (en) * 2014-12-05 2016-06-09 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016100452A2 (en) * 2014-12-17 2016-06-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
WO2019040706A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING VITILIGO
ES2925450T3 (es) * 2017-11-06 2022-10-18 Bristol Myers Squibb Co Compuestos de isofuranona útiles como inhibidores de HPK1
EA202092759A1 (ru) * 2018-05-24 2021-04-09 Астразенека Аб ФУМАРАТНАЯ СОЛЬ 5-((5-МЕТИЛ-2-((3,4,5-ТРИМЕТИЛФЕНИЛ)АМИНО)ПИРИМИДИН-4-ИЛ)АМИНО)БЕНЗО[d]ОКСАЗОЛ-2(3H)-ОНА
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110078633B (zh) * 2019-05-24 2021-05-11 爱斯特（成都）生物制药股份有限公司 一种4-氟-3-甲氧基-5-甲基苯胺盐酸盐制备方法
WO2021239133A1 (zh) * 2020-05-29 2021-12-02 南京正大天晴制药有限公司 作为axl抑制剂的嘧啶类化合物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
CA2031376A1 (en) 1989-12-04 1991-06-05 Bahram Farhadieh Single layer transdermal drug administration system
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
WO1993011938A1 (en) 1991-12-18 1993-06-24 Minnesota Mining And Manufacturing Company Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
US8178671B2 (en) 2003-07-30 2012-05-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CA2604551A1 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
CN101282945A (zh) * 2005-06-08 2008-10-08 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8393954B2 (en) 2006-12-29 2013-03-12 Cfph, Llc Top performers
WO2008118822A1 (en) * 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2009063240A1 (en) * 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
MX2011007750A (es) * 2009-01-23 2011-09-29 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la ruta jak.
PT2598500T (pt) * 2010-07-28 2021-07-22 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
JP6129155B2 (ja) * 2011-04-12 2017-05-17 ライジェル ファーマシューティカルズ， インコーポレイテッド 同種移植片拒絶反応を抑制する方法

Also Published As

Publication number Publication date
PL2598500T3 (pl) 2021-11-29
US20150259332A1 (en) 2015-09-17
ES2880622T3 (es) 2021-11-25
US11174251B2 (en) 2021-11-16
US20220024907A1 (en) 2022-01-27
US9067925B2 (en) 2015-06-30
AR119882A2 (es) 2022-01-19
US20170158683A1 (en) 2017-06-08
MX2013000757A (es) 2013-04-29
US10479783B2 (en) 2019-11-19
JP6073221B2 (ja) 2017-02-01
PT2598500T (pt) 2021-07-22
AU2011282742B2 (en) 2015-08-27
AU2011282742A2 (en) 2013-04-04
US9920041B2 (en) 2018-03-20
MX347331B (es) 2017-04-21
KR101937495B1 (ko) 2019-01-10
BR112013001632A2 (pt) 2016-05-24
EP2598500A1 (en) 2013-06-05
USRE47396E1 (en) 2019-05-21
TW201209053A (en) 2012-03-01
AR082408A1 (es) 2012-12-05
US20120028923A1 (en) 2012-02-02
US9611260B2 (en) 2017-04-04
CA2804199A1 (en) 2012-02-02
DK2598500T3 (da) 2021-07-26
CA2804199C (en) 2020-05-12
IL223855A (en) 2016-05-31
US20200115371A1 (en) 2020-04-16
KR20130132406A (ko) 2013-12-04
TWI582090B (zh) 2017-05-11
JP2013536179A (ja) 2013-09-19
CN103201280B (zh) 2016-08-10
ZA201300388B (en) 2013-09-25
BR112013001632B1 (pt) 2021-05-25
WO2012015972A1 (en) 2012-02-02
US20180162848A1 (en) 2018-06-14
US20130090310A1 (en) 2013-04-11
MX2020009397A (es) 2020-12-03
JP2017061518A (ja) 2017-03-30
EP2598500B1 (en) 2021-05-19
US8343954B2 (en) 2013-01-01
RU2015122016A (ru) 2016-12-27
CN103201280A (zh) 2013-07-10
RU2672100C2 (ru) 2018-11-12
AU2011282742A1 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
EA201390015A1 (ru) Композиции и способы ингибирования пути jak
EA201190082A1 (ru) Композиции и способы для ингибирования сигнального пути jak
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
PL2250172T3 (pl) Pirolopirazynowe inhibitory kinazy
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
MX2010008198A (es) Inhibidores de cinasa de pirrolopirazina.
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
MX340402B (es) Inhibidores triciclicos de cinasas.
MX2013012776A (es) Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2012000711A (es) Inhibidores de pirrolopirazina de cinasas.
UA107796C2 (en) Tetracyclic compound
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
MX2012002542A (es) Compuestos y composiciones como inhibidores de cinasa de proteina.
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201100447A1 (ru) Органические соединения
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
JO2998B1 (ar) مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
EA201101396A1 (ru) Ингибиторы аутотаксина
EA201100749A1 (ru) Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
EA201300080A1 (ru) Дипиридильные производные, пригодные для лечения заболеваний, индуцированных киназами